https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-30 / Oncoimmunology 2018;7(12):e1474318
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-30 / Oncoimmunology 2018;7(12):e14743182018-07-30 00:00:002018-07-30 00:00:00Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-12-12 / Clin. Cancer Res. 2018 Feb;24(4):766-776
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-12-12 / Clin. Cancer Res. 2018 Feb;24(4):766-7762017-12-12 00:00:002019-02-15 08:50:39Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-08-24 / Front Oncol 2017;7:179
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-08-24 / Front Oncol 2017;7:1792017-08-24 00:00:002017-08-24 00:00:00Oncolytic Viral Therapy for Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-01 / Am. J. Respir. Crit. Care Med. 2016 05;193(9):1023-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-01 / Am. J. Respir. Crit. Care Med. 2016 05;193(9):1023-312016-05-01 00:00:002020-09-07 08:01:30Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-02-01 / Transl Lung Cancer Res 2014 Feb;3(1):34-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-02-01 / Transl Lung Cancer Res 2014 Feb;3(1):34-452014-02-01 00:00:002014-02-01 00:00:00Immunotherapy prospects in the treatment of lung cancer and mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-24 / J Extracell Vesicles 2013;2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-24 / J Extracell Vesicles 2013;22013-10-24 00:00:002019-02-15 08:46:15Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-28 / J Med Case Rep 2012 Dec;6:427
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-28 / J Med Case Rep 2012 Dec;6:4272012-12-28 00:00:002012-12-28 00:00:00A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-10-01 / Immunotherapy 2012 Oct;4(10):1011-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-10-01 / Immunotherapy 2012 Oct;4(10):1011-222012-10-01 00:00:002019-02-15 08:50:37Dendritic cell-based immunotherapy in mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-06-28 / Lancet Oncol. 2012 Jul;13(7):e301-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-06-28 / Lancet Oncol. 2012 Jul;13(7):e301-102012-06-28 00:00:002012-06-28 00:00:00Immunotherapies for non-small-cell lung cancer and mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-21 / Mol. Cancer Ther. 2010 Oct;9(10):2761-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-21 / Mol. Cancer Ther. 2010 Oct;9(10):2761-92010-09-21 00:00:002010-09-21 00:00:00Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma
